**** SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS ****
+----------------+--------------------------------------+----------+-----------+
| CAS# | Chemical Name | % | EINECS# |
|----------------|--------------------------------------|----------|-----------|
| 56243-25-5 |1-Benzyl-4-Cyano-4-Phenylpiperidine Hy| 99+ | unlisted |
| |drochloride | | |
+----------------+--------------------------------------+----------+-----------+
Hazard Symbols: XN
Risk Phrases: 20/21/22
**** SECTION 3 - HAZARDS IDENTIFICATION ****
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.The
toxicological properties of this material have not been fully
investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be metabolized to cyanide which in
turn acts by inhibiting cytochrome oxidase impairing cellular
respiration.
Ingestion:
May cause irritation of the digestive tract. May cause cardiac
disturbances. The toxicological properties of this substance have not
been fully investigated. May cause central nervous system depression.
Metabolism may release cyanide, which may result in headache,
dizziness, weakness, collapse, unconsciousness and possible death.
Ingestion may result in symptoms similar to cyanide poisoning which
is characterized by asphyxiation.
Inhalation:
May cause respiratory tract irritation. The toxicological properties
of this substance have not been fully investigated. May cause cardiac
abnormalities. May be metabolized to cyanide which in turns act by
inhibiting cytochrome oxidase impairing cellular respiration.
Inhalation may result in symptoms similar to cyanide poisoning which
include tachypnea, hyperpnea (abnormally rapid or deep breathing),
and dyspnea (labored breathing) followed rapidly by respiratory
depression. Pulmonary edema may occur. Inhalation at high
concentrations may cause CNS depression and asphixiation.
Chronic:
No information found. May be metabolized to cyanide which in turn
acts by inhibiting cytochrome oxidase impairing cellular
respiration. Chronic exposure to cyanide solutions may lead to the
development of a "cyanide" rash, characterized by itching, and by
macular, papular, and vesicular eruptions, and may be accompanied by
secondary infections. Exposure to small amounts of cyanide compounds
over long periods of time is reported to cause loss of appetite,
headache, weakness, nausea, dizziness, and symptoms of irritation of
the upper respiratory tract and eyes.
**** SECTION 4 - FIRST AID MEASURES ****
Eyes:
Immediately flush eyes with plenty of water for at least 15 minutes,
occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15
minutes while removing contaminated clothing and shoes. Wash clothing
before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical
aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and
drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If breathing
is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth
resuscitation. If breathing has ceased apply artificial respiration
using oxygen and a suitable mechanical device such as a bag and a
mask.
Notes to Physician:
May be partially metabolized to cyanide in the body.
Antidote:
Always have a cyanide antidote kit on hand when working with cyanide
compounds. Get medical advice to use.
**** SECTION 5 - FIRE FIGHTING MEASURES ****
General Information:
As in any fire, wear a self-contained breathing apparatus in
pressure-demand, MSHA/NIOSH (approved or equivalent), and full
protective gear. During a fire, irritating and highly toxic gases
may be generated by thermal decomposition or combustion. Runoff from
fire control or dilution water may cause pollution.
Extinguishing Media:
Use agent most appropriate to extinguish fire. For small fires, use
dry chemical, carbon dioxide, or water spray. For large fires, use
dry chemical, carbon dioxide, alcohol-resistant foam, or water spray.
**** SECTION 6 - ACCIDENTAL RELEASE MEASURES ****
General Information: Use proper personal protective equipment as indicated
in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal
container. Clean up spills immediately, observing precautions in the
Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.
**** SECTION 7 - HANDLING and STORAGE ****
Handling:
Wash thoroughly after handling. Remove contaminated clothing and
wash before reuse. Use with adequate ventilation. Minimize dust
generation and accumulation. Avoid contact with eyes, skin, and
clothing. Keep container tightly closed. Avoid ingestion and
inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry,
well-ventilated area away from incompatible substances.
**** SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION ****
Engineering Controls:
Facilities storing or utilizing this material should be equipped
with an eyewash facility and a safety shower. Use process enclosure,
local exhaust ventilation, or other engineering controls to control
airborne levels.
Exposure Limits
CAS# 56243-25-5:
Personal Protective Equipment
Eyes:
Wear appropriate protective eyeglasses or chemical
safety goggles as described by OSHA's eye and face
protection regulations in 29 CFR 1910.133 or European
Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin
exposure.
Clothing:
Wear appropriate protective clothing to minimize
contact with skin.
Respirators:
Follow the OSHA respirator regulations found in 29
CFR 1910.134 or European Standard EN 149. Use a
NIOSH/MSHA or European Standard EN 149 approved
respirator if exposure limits are exceeded or if
irritation or other symptoms are experienced.
**** SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES ****
Physical State: Powder
Color: very light beige
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 250.00 - 259.00 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C19H20N2.HCl
Molecular Weight: 312.83
**** SECTION 10 - STABILITY AND REACTIVITY ****
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong
oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, hydrogen cyanide, nitrogen oxides, carbon
monoxide, irritating and toxic fumes and gases, carbon dioxide,
nitrogen.
Hazardous Polymerization: Has not been reported.
**** SECTION 11 - TOXICOLOGICAL INFORMATION ****
RTECS#:
CAS# 56243-25-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Benzyl-4-Cyano-4-Phenylpiperidine Hydrochloride -
Not listed by ACGIH, IARC, or NTP.
**** SECTION 12 - ECOLOGICAL INFORMATION ****
**** SECTION 13 - DISPOSAL CONSIDERATIONS ****
Dispose of in a manner consistent with federal, state, and local regulations.
**** SECTION 14 - TRANSPORT INFORMATION ****
IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III
**** SECTION 15 - REGULATORY INFORMATION ****
European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 56243-25-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 56243-25-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 56243-25-5 is not listed on the TSCA inventory.
It is for research and development use only.
**** SECTION 16 - ADDITIONAL INFORMATION ****
MSDS Creation Date: 9/02/1997 Revision #4 Date: 3/18/2003
The information above is believed to be accurate and represents the best
information currently available to us. However, we make no warranty of
merchantability or any other warranty, express or implied, with respect to
such information, and we assume no liability resulting from its use. Users
should make their own investigations to determine the suitability of the
information for their particular purposes. In no way shall the company be
liable for any claims, losses, or damages of any third party or for lost
profits or any special, indirect, incidental, consequential or exemplary
damages, howsoever arising, even if the company has been advised of
the possibility of such damages.
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
|
|
|
| ALL MSDS PAGES IN THIS GROUP
| | NAME | CAS |
|
n-Methyl-2,2,2-trifluoroacetamide, 98%
| 815-06-5 |
|
D-(+)-alpha-methylbenzylamine, 99+%,(99% e.e.)
| 3886-69-9 |
|
Rhodamine 123, 99+% (UV-Vis)
| 62669-70-9 |
|
3,5-Dimethylisoxazole, 99%
| 300-87-8 |
|
1-Benzyl-4-Cyano-4-Phenylpiperidine Hydrochloride, 99+%
| 56243-25-5 |
|
Inosine 5'-diphosphate, trisodium salt hydrate
| 81012-88-6 |
|
Azure b (cert)
| 531-55-5 |
|
Methyl propionate, 99+% (gc)
| 554-12-1 |
|
4,4'-Dimethoxybenzil, 99+%
| 1226-42-2 |
|
2-Aminobenzophenone, 98%
| 2835-77-0 |
|
Thallous ethoxide, 98%
| 20398-06-5 |
|
4-Amino-3-hydroxy-1-naphthalenesulfonic acid, reagent ACS, 98+%
| 116-63-2 |
|
N-Phenylmethanesulfonamide
| 1197-22-4 |
|
2'-Deoxyinosine, 99%
| 890-38-0 |
|
Naphthol AS-BI phosphate, 95% (titr.)
| 1919-91-1 |
|
o-Cresolphthalein complexone
| 2411-89-4 |
|
(R)-2-Hydroxy-3-buten-1-yl p-tosylate, 99% (gc)
| 138249-07-7 |
|
Isobutyronitrile, 99%
| 78-82-0 |
|
Betaine monohydrate, 99%
| 590-47-6 |
|
Amberlite XAD-2
| 9060-05-3 |
|
Shikimic Acid, 98%
| 138-59-0 |
|
(2r,3s)-1-carboxy-4-tert.-butyl-2,3-di-
| |
|
6-Methoxypurine, 99+%
| 1074-89-1 |
|
3,4,9,10-Perylenetetracarboxylic dianhydride, 98%
| 128-69-8 |
|
Pectin, Pract.
| 9000-69-5 |
|
Ethyl (2r)-2,3-epoxypropanoate, 97%
| 111058-33-4 |
|
3-Glycidoxypropyltrimethoxysilane, 97+%
| 2530-83-8 |
|
??3,4??-Dibenzo-21-Crown-7, 98%
| 14098-41-0 |
|
2-Chloro-6-methoxybenzonitrile, 97%
| 6575-10-6 |
|
Salicylhydrazide, 98%
| 936-02-7 |
|
Calcium Propionate, 98% (Titr., on Dry Basis)
| 4075-81-4 |
|
2-Bromofluorobenzene, 99%
| 1072-85-1 |
|
Plumbagin, 99+%
| 481-42-5 |
|
1-Iodohexadecane, 95% (GC)
| 544-77-4 |
|
2,3,5-Trichlorobenzaldehyde,97%
| 56961-75-2 |
|
N-Iodoacetyl-N'-(5-sulfo-1-naphthyl)- ethylenediamine
| 36930-63-9 |
|
Chloramine-T Trihydrate, 98%
| 7080-50-4 |
|
DL-Methionine Sulfoxide, 99%
| 454-41-1 |
|
4'-(Imidazol-1-yl)acetophenone, 97%
| 10041-06-2 |
|
Iproniazid Phosphate, 97%
| 305-33-9 |
|
Ethyl 3-thiopheneacetate, 98%
| 37784-63-7 |
|
2,6-Dimethoxyphenol, 99+% (gc)
| 91-10-1 |
|
o-Tolylurea
| 614-77-7 |
|
3,5-Dimethoxy-4-Hydroxybenzaldehyde, 98%
| 134-96-3 |
|
Lobeline Hydrochloride, 97%
| 63990-84-1 |
|
3',4'-Dichloroacetophenone, 99%
| 2642-63-9 |
|
2-Methyl-1,2,3,4-Tetrahydro-6,7-Isoquinolinediol Hydrochloride, 98%
| 63937-92-8 |
|
1-Benzyl-2-pyrrolidinone, 97%
| 5291-77-0 |
|
Benzopurpurin 4b, 95% (uv-vis)
| 992-59-6 |
|
7-Dehydrocholesterol, 97.5+%, Contains Approx. 1 Mole of MeOH of
| 434-16-2 |
|
|